HK Stock Market Move | BAO PHARMA-B(02659) Surges Over 9% in Early Trading as Clinical Research and Commercialization of Core Products Advance Steadily

BAO PHARMA-B (02659) surged over 9% in early trading. As of press time, it was up 6.78% at HK$14.8, with a turnover of HK$11.0487 million. On the news front, in the first half of the year, Bao Pharma ushered in a harvest period for commercialization, with the company officially entering the fast lane of dual-driven commercialization and internationalization. Guosen pointed out that KJ017 was approved for marketing in China in March 2026 for adjunctive subcutaneous infusion, and two Phase 3 clinical study datasets were published in the *European Journal of Pharmaceutics and Biopharmaceutics*; the company continues to expand cooperation, and as of its 2026 interim report, more than 60 partners had used KJ017 for product development, with projects covering various stages from early research to clinical development. In addition, the domestic marketing application for KJ103 for desensitization treatment before kidney transplantation was submitted in May 2026 and accepted by the drug regulator; the Phase 3 clinical study for desensitization treatment in highly sensitized kidney transplant patients reached its primary endpoint in March 2026, with rapid desensitization effects, a high success rate, and good safety; data from the Phase 2 clinical study for anti-GBM disease were presented at the European Renal Association Congress in June 2026, preliminarily demonstrating clinical value. Since its launch, SJ02, under the market promotion of partners, has completed online procurement platform listing and market access work in 29 provinces across China, covering more than 70 medical institutions.